<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526549</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-304</org_study_id>
    <nct_id>NCT03526549</nct_id>
  </id_info>
  <brief_title>Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite)</brief_title>
  <official_title>A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835
      lasts in the treatment of Cellulite.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who lose their response as compared to Day 71 of EN3835-302/303</measure>
    <time_frame>60 months</time_frame>
    <description>Measured by proportion of subjects that both the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) scores/ratings return to baseline of the double-blind studies (EN3835-302/303) or worse; both CR-PCSS and PR-PCSS worsened 2-levels compared to the score at Day 71 of the double-blind studies (EN3835-302/303); either CR-PCSS or PR-PCSS worsened 2-levels compared to the scores at Day 71 of the double-blind studies (EN3835-302/303); both CR-PCSS and PR-PCSS scores worsened by 1-level compared to the corresponding scores at Day 71 of the double-blind studies (EN3835-302/303)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the PR-PCSS</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 5 levels, 0=None to 4=Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the CR-PCSS</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 5 levels, 0=None to 4=Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Patient Reported Cellulite Impact Scale (PR-CIS) from Baseline (Day 1) of EN3835-302/303</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 11 levels; 0=Not at All to 10=Extremely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the Subject Satisfaction with cellulite treatment</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 5 levels; -2=Very dissatisfied to +2=Very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the subject self-rating scale</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 7 levels; 0=Extremely dissatisfied to 6=Extremely satisfied</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>EN3835 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN3835</intervention_name>
    <description>Collagenase Clostridium Histolyticum (CCH)</description>
    <arm_group_label>EN3835 Active</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria through Day 180:

          -  Voluntarily sign and date an informed consent agreement

          -  Have participated in and completed the double-blind Phase 3 study EN3835-302 or
             EN3835-303

          -  Be willing to apply sunscreen to the buttocks before each exposure to the sun while
             participating in the study during this period

          -  Be judged in good health

          -  Have a negative serum pregnancy test and be using an effective method of birth control

        Inclusion Criteria beyond Day 180

          -  Received active EN3835 in the double-blind studies (EN3835-302/303) and not placebo

          -  Be willing to apply sunscreen to the buttocks before each exposure to sun while
             participating in any re-treatment portion of the study.

          -  Have a negative urine pregnancy test and use an effective method of birth control, as
             appropriate

        Exclusion Criteria through Day 180:

          -  Intends to or has used other treatments for EFP on the buttocks at any time during the
             study

          -  Intends to use tanning spray or tanning booths during the study

        Exclusion Criteria beyond Day 180:

          -  Intends to or has used other treatments for EFP on the buttocks at any time during the
             study

          -  Intends to use tanning spray or tanning booths during the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education and research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

